

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Aquarius Surgical Technologies Inc. (the "Issuer").

Trading Symbol: ASTI

Number of Outstanding Listed Securities: 19,578,639

Date: May 6, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

After the successful completion of product evaluations ASTI, in April, completed the sale and installation of three new HYPHO holmium lasers (for kidney and bladder stones) in hospitals in Florida, Pennsylvania and South Dakota.

Continuous revenue streams will be generated by these three facilities from the ongoing purchase of consumables, and in that regard, they have each already placed orders for ASTIs single-use fibers (one per procedure). The ongoing revenue stream from these single-use fibers will continue in the form of monthly orders.

As demand for this unique technology platform continues to grow, and in a proactive effort to maintain timely delivery in support of future revenue streams, ASTI has five lasers in production now which will be ready for delivery in May to five new hospitals who have committed to purchase the HYPHO holmium laser and fibers.

In expanding ASTIs marketing exposure at the American Urology Association (AUA) annual meeting and exhibition in Chicago (the largest meeting of its kind in the world) on May 3 – 6, 2019, ASTI has been invited to showcase our new HYPHO holmium laser for bladder and kidney stones at the AUA Flexible Ureteroscopy Course scheduled for Sunday May 5th. Ureteroscopy is a minimally invasive procedure for breaking up kidney and bladder stones without the requirement for an incision, currently estimated to be a \$10 billion+ market.

2. Provide a general overview and discussion of the activities of management.

On the financing side, the issuer has been working closely with CHF Capital Markets to disseminate our story with encouraging results through a number of small group presentations to brokers and HNW investors.

More meetings are planned in the weeks ahead which are expected to lead to a financing in the near future.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the

relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common	11,000	Issued at \$0.43182	Payment for services
Common	12,500	Issued at \$0.40	Payment for services

(1) State aggregate proceeds and intended allocation of proceeds.

- 15. Provide details of any loans to or by Related Persons.
None
- 16. Provide details of any changes in directors, officers or committee members.
None
- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
No current changes

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 6, 2019

N. Gary Van Nest
Name of Director or Senior
Officer

Signed "Gary Van Nest"
Signature
CEO
Official Capacity

Issuer Details		For Month End	Date of Report YY/MM/D
Name of Issuer Aquarius Surgical Technologies Inc.		April 2019	19/05/6
Issuer Address 89 Scollard Street			
City/Province/Postal Code Toronto, ON M5R 1G4		Issuer Fax No. (902)484-7599	Issuer Telephone No. (902) 496-7594
Contact Name Gary Van Nest		Contact Position CEO	Contact Telephone No (647) 308-0685.
Contact Email Address gary@sinaltainvestments.com		Web Site Address www.surgicallasersinc.com	